Dr. Secord on Treating Patients with Platinum Sensitive Ovarian Cancer

Video

Angeles A. Secord, MD, discusses treating patients with platinum-sensitive ovarian cancer.

Angeles A. Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses treating patients with platinum-sensitive ovarian cancer.

Often, patients with platinum-sensitive ovarian cancer do not want to restart chemotherapy, so other therapeutic options are needed, Secord says. The integration of PARP inhibitors into the treatment paradigm has called a need to evaluate patients regarding what frontline treatments they received to determine if they are eligible for a PARP inhibitor, Secord says. 

Moreover, patients are evaluated in terms of their biomarkers, including whether they harbor BRCA1/2 mutations or if their tumor is characterized by homologous recombination deficiency or proficiency, also known as genomic instability, Secord explains.

Overall, if a patient has not received a PARP inhibitor in the frontline setting and they harbor BRCA1/2 mutations or genomic instability within their tumor, they should be considered for PARP inhibitor therapy. Additionally, the use of bevacizumab (Avastin) as a therapeutic option in the maintenance setting, as well as with concurrent chemotherapy, should also be discussed with the patient, Secord concludes.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH